CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
Jae H. Park(Memorial Sloan Kettering Cancer Center), Karthik Nath(Memorial Sloan Kettering Cancer Center), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Craig S. Sauter(Cleveland Clinic), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Gunjan L. Shah(Memorial Sloan Kettering Cancer Center), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Richard J. Lin(Memorial Sloan Kettering Cancer Center), Michael Scordo(Memorial Sloan Kettering Cancer Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Roni Shouval(Memorial Sloan Kettering Cancer Center), Ana Alarcón Tomás(Memorial Sloan Kettering Cancer Center), Elizabeth Cathcart(Memorial Sloan Kettering Cancer Center), Elena Mead(Memorial Sloan Kettering Cancer Center), Bianca Santomasso(Memorial Sloan Kettering Cancer Center), Andrei I. Holodny(Memorial Sloan Kettering Cancer Center), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Kettering University)
Cited by 159Open Access
Abstract
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al.|New England Journal of Medicine|2017|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al.|New England Journal of Medicine|2018|5.6k
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al.|Journal of Clinical Oncology|2014|5.5k